Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)
ASN90, an O-GlcNAcase inhibitor, is a new chemical entity at clinical stage and a promising candidate for the treatment of PSP, a disorder with a...